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Convergence of Wnt/b-catenin and mTOR Signaling in Liver Physiology and 
Hepatocellular Carcinoma 
Adeola O. Adebayo Michael, Junyan Tao, Satdarshan P. Monga. 
Division of Experimental Pathology, University of Pittsburgh, School of Medicine, 
Pittsburgh PA,  
Previous studies showed that the mechanistic Target Of Rapamycin (mTOR), a central 
regulator of cell growth, is activated in the early stages of preneoplastic foci 
development. We have also shown enhanced mTOR activity in hepatocellular 
carcinoma (HCC) that occurs due to cooperation of point-mutant b-catenin and hMet 
coexpression in liver. These signaling pathways, mTOR and Wnt/b-catenin, have been 
singly implicated in the pathogenesis of HCC, thus, our aim was to investigate their 
interactions in hepatic pathophysiology. We hypothesized that mTOR is regulated by b-
catenin in hepatic physiology and pathology to contribute to HCC. To test this 
hypothesis, we silenced b-catenin in HCC cells to examine impact on mTOR. We 
utilized liver-specific b-catenin knockout (KO1) and Wnt co-receptor LRP5/6 double KO 
(KO2) to examine mTOR.  Lastly, we examined the effect of mTOR modulation in HCC 
model responsive to b-catenin inhibition. b-Catenin knockdown in Hep3B cells 
decreased mTOR and p-mTOR, while mTOR knockdown had no impact on b-catenin. 
We identified phospho-mTORC1 representing the active form of mTOR to be located in 
pericentral hepatocytes, same location where b-catenin is constitutively active. 
Intriguingly, we identified absence of p-mTOR in pericentral hepatocytes in both KO1 
and KO2. Lastly, we observed that the pharmacological co-inhibition of mTOR and Met 
in our HCC model attenuates tumor burden and increased survival. Thus, our studies 
provide evidence of interactions between mTOR and Wnt/b-catenin signaling in liver 
homeostasis and in HCC.  We demonstrate that the combination of mTOR and Met 
inhibitors is an effective approach to reduce liver tumor burden and may represent 
candidate chemotherapeutic strategy for the distinct subset, which represents 10% of all 
HCC. 
 
